openPR Logo
Press release

Deep Brain Stimulation Devices Market for Parkinson's Disease Industry Trends, Growth Rate With CAGR Analysis 2020

02-24-2017 02:04 PM CET | IT, New Media & Software

Press release from: TMR - Research Reports

Deep Brain Stimulation Devices Market for Parkinson's Disease

Deep Brain Stimulation Devices Market: Snapshot

The rise in the global geriatric population, increasing number of patients suffering from Parkinson’s diseases (PD), and growing awareness about neurological movement disorders among patients have triggered the growth of the deep brain stimulation devices market. Globally, neurological disorders are one of the major causes of morality and accounts for approximately 12% of the deaths per annum. Of these, cerebrovascular diseases account for 85% deaths. Parkinson’s disease is the most common neurological disorders after Alzheimer’s disease. Symptoms associated with this disease include tremors, slowness of movement, muscle stiffness, and trouble with balance. Drug therapy is the most effective treatment option available to control PD in the initial stages. Though there are several stages of PD, surgical treatment using deep brain stimulation (DBS) devices is more frequently used to control symptoms of disease. DBS devices are an effective, clinically proven, and legally approved advanced treatment option for milk to serve PD.

Obtain the PDF containing Upcoming Market Trends of Deep Brain Stimulation Devices for Parkinson's Disease at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1435

The market for deep brain stimulation devices for Parkinson’s diseases is expected to grow at a robust rate of 11% during the forecast period of 2014 to 2020. The opportunity in the market is estimated to reach US$3.2 bn by the end of 2020. The growing burden of PD on healthcare systems, along with the uncertainty of economic conditions in some developed economies such as the U.S. and Europe has forced original equipment manufacturers (OEMs) to develop cost-effective devices for PD treatment.

North America to Maintain Most Prominent Demand for DBS Devices

Geographically, the global market for deep brain stimulation devices market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America currently serves the maximum demand for DBS devices for Pakistan’s disease, and is expected to maintain its leading position throughout the forecast period from 2014 to 2020, growing at a CAGR of 9.3% in terms of revenue. The region is expected to gain market share of 44.2% by the end of 2020. The key factors attributed to their leading position in the global market are high prevalence and incidence rate of Parkinson’s diseases in the region, aging population, demand for advanced deep brain stimulation devices and presence of high disposable income in the region.

The U.S. was the largest market for DBS devices for the treatment of Parkinson’s disease. According to the centers for Disease Control and Prevention, Pakistan’s disease is the 14th leading cause of death in the U.S. At present, approximately 1 million to 1.2 million people in the U.S. are suffering from Parkinson’s disease. The U.S. is a major R&D and technology center in the world and holds a key share in the healthcare industry with advanced technologies, presence of top companies, and relentless developments. Significant R&D activities are currently being undertaken by the U.S. Government to introduce innovative drugs and devices to help the society in disease management.

Canada is another prominent market for DBS devices for the treatment of Parkinson’s disease. According to the Parkinson’s Society Canada, approximately 100,000 people in Canada suffer from Parkinson’s disease. The disease affects nearly 1% of the population above 65 years of age and 2% of those about 70 years of age. Canada’s healthcare system has implemented a publicly funded insurance program wherein the costs are controlled by both hospitals and doctors. North America was followed by Europe as the widest market for the DBS devices for Parkinson’s diseases. The region is expected to contribute to 33.7% of the demand by the end of the forecast period of 2014–2020. Asia Pacific, though currently accounts for the third most prominent market for deep brain stimulation devices, it is expected to expand at a healthy CAGR of 8% during the forecast period of 2014–2020.

Read the Present Market Status of Deep Brain Stimulation Devices for Parkinson's Disease at: http://www.transparencymarketresearch.com/deep-brain-stimulator-market.html

Some of the key players in global deep brain stimulation devices market are Aleva Neurotherapeutics SA, Boston Scientific Corporation, Medtronic, Inc., and St. Jude Medical, Inc.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deep Brain Stimulation Devices Market for Parkinson's Disease Industry Trends, Growth Rate With CAGR Analysis 2020 here

News-ID: 448154 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for Parkinson

QualitySolicitors Parkinson Wright invest in the future
QualitySolicitors Parkinson Wright has selected Liberate from Linetime as its business-wide legal services software platform. The Worcestershire based practice, with over 100 staff, operate from 4 offices and have a highly regarded reputation for their services including residential property, private client, family, dispute resolution and commercial. The firm also has its own estate agency. The firm recognised that to continue delivering high quality services to its clients it needed to provide
Wolff Parkinson White syndrome Market found Future opportunities of 2023
The Analysis presents the study of Global Wolff Parkinson White syndrome Market facilitating the regional and country wise analysis covering the strategic analysis of each market player and the market share they hold Wolff Parkinson White Syndrome Market Information: By Types (Type A, Type B) By Diagnosis (Electrocardiogram (ECG), Electrophysiological Testing, Others) By Treatment (Drugs (Anti-Arrhythmic, Beta-Blockers, Others), Cardioversion, Radiofrequency Catheter Ablation, Surgery, Artificial Pacemaker, Others) By End Users - Global
PARKINSON RESEARCH FOUNDATION Announces Director of Patient Programs, Services a …
The Parkinson Research Foundation is pleased to announce that Marilyn Tait has joined the foundation as the Director of Patient Programs, Services and Advocacy. Tait, is a graduate of Thomas Jefferson University School of Nursing in Philadelphia, Pennsylvania. Tait has forty years experience in healthcare marketing and program development. After specializing in oncology for 30 years, Tait embarked on her new career at a time in her life when
PARKINSON RESEARCH FOUNDATION’S (PRF) WESTERN CARIBBEAN FOURTH EDUCATIONAL CRU …
The Parkinson Research Foundation (PRF), a non-profit organization with a dedicated patient education program, will return to the Western Caribbean for its fourth educational cruise. PRF developed its educational cruise program to give Parkinson patients, caregivers family and loved ones unrivaled access to experts in the movement-disorder field. After visiting the Bahamas and Alaska on the first two respective PRF cruises, PRF’s ventured to the Western Caribbean on its most
PARKINSON RESEARCH FOUNDATION (PRF) Develops New Patient Outreach Program
One of the principal missions of the Parkinson Research Foundation (PRF) that distinguishes it from other Parkinson organizations is PRF’s focus on patient education; specifically education that enables Parkinson patients and their caregivers to live fuller and more comfortable lives with Parkinson's disease. The Foundation’s educational events, including educational cruises, gather leading Parkinson experts, therapists and nutritionists from across the country to offer life-changing tools and knowledge for individuals affected
Parkinson`s Disease:New Hope Educational Conference
PARKINSON’S DISEASE: NEW HOPE EDUCATIONAL CONFERENCE Become knowledgeable about the advancements in surgery The Parkinson Research Foundation is proud to announce that Dr. James Schumacher will be speaking about advances in surgery at our fourth annual New Hope for Parkinson’s conference on November 1st in Boca Raton. Dr. Schumacher is an internationally known expert in the field of neurosurgical treatment of Parkinson’s disease and movement disorders. He has an extensive background and